AACR: Akeso’s Cadonilimab Shows 1L Potential In Adenocarcinoma

Promising Interim Phase III Data

 
• By Dexter Jie Yan
  
gastric cancer
positive results help Akeso's cadonilimab position as standard 1L therapy for G/GEJ adenocarcinoma • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia